论文部分内容阅读
单纯红细胞再生障碍贫血(PRCA)的主要发病机制之一是T细胞功能紊乱介导的造血抑制。而CsA是以T细胞为主要作用靶点的免疫抑制剂,文献报道CsA治疗PRCA有效率为82%,是目前公认的治疗获得性PRCA首选药。
One of the main pathogenesis of pure red cell aplastic anemia (PRCA) is hematopoietic suppression mediated by T cell dysfunction. CsA is an immunosuppressive agent that targets T cells as the main target. CsA is reported to be effective in treating PRCA with an effective rate of 82%. It is currently recognized as the preferred drug for treatment-acquired PRCA.